Minimally Clinically Important Difference of the Clinical Assessment Scale in Autoimmune Encephalitis

Annals of Clinical and Translational Neurology 2026 Open access

Read full text
Authors: Yihui Goh, Yoon Hee Shin, Soo Hyun Ahn, Su Yee Mon, Soo Jean Shin, Woo-Jin Lee, Yoonhyuk Jang, Myoung‐jin Jang, S. J. Lee
DOI: 10.1002/acn3.70360
Cited by: 0
References: 18

Abstract

The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) tracks disease severity in autoimmune encephalitis (AE), but no threshold for significant change exists. We aimed to determine the minimally clinically important difference (MCID) for CASE. Using our AE cohort, receiver operating characteristic analyses were anchored to ≥ 1-point improvement in mRS over 3-month intervals. Among 222 AE patients (65 NMDAR, 49 LGI1, and 108 seronegative AE), a 30% CASE reduction showed good discriminatory performance for mRS improvement in the first 6 months, particularly in NMDAR and seronegative subgroups. A 30% CASE reduction may standardize AE response definitions.

Fields of Study & Subjects

Autoimmune Neurological Disorders and Treatments Myasthenia Gravis and Thymoma Peripheral Neuropathies and Disorders

Publication details

Journal / source
Annals of Clinical and Translational Neurology
Volume
13
Issue
6
Pages
1283–1288
Publication date
5 March 2026
Language
EN